Inherent or acquired drug resistance is one of the major problems in chemotherapy. The mechanisms by which cancer cells survive and escape the cytotoxic eects of chemotherapeutic agents are essentially unknown. In the present study, we demonstrate that in the MDA-MB-231 and MDA-MB-435 breast cancer cells, ligation of b1 integrins by their extracellular matrix ligands inhibits signi®cantly apoptosis induced by paclitaxel and vincristine, two microtubule-directed chemotherapeutic agents that are widely used in the therapy of breast cancer. We show that b1 integrin signaling inhibits drug-induced apoptosis by inhibiting the release of cytochrome c from the mitochondria in response to drug treatment. Further, integrin-mediated protection from drug-induced apoptosis and inhibition of cytochrome c release are dependent on the activation of the PI 3-kinase/Akt pathway. Our results identify b1 integrin signaling as an important survival pathway in drug-induced apoptosis in breast cancer cells and suggest that activation of this pathway may contribute to the generation of drug resistance. Oncogene (2001) 20, 4995 ± 5004.
Introduction
One of the most important advances in oncology came out of the understanding that most patients with primary breast cancer have disseminated tumors at the time of diagnosis and that increased survival results only from eective systemic therapy used in conjunction of operation (Fisher et al., 1997) . While signi®cant advances have been made with adjuvant therapy, optimal therapy has not been de®ned for any subset of patients, however. One of the hurdles in the adjuvant chemotherapy, especially in the case of metastatic breast cancer, is the inherent or acquired drug resistance of the tumor (Lebwohl and Canetta, 1999) . Thus, several clinical trials are underway to evaluate the optimal adjuvant chemotherapy to overcome drug resistance; at present, paclitaxel/docetaxel alone or in combination with e.g. doxorubicin (and with tamoxifen, trastuzumab (Herceptin) and/or aromatase inhibitors as hormonal agents) are most intensely studied (Fornier et al., 1999) . In addition to the ongoing clinical trials, it is clear that a better understanding of the cell biology of drug resistance could provide immense help when designing new therapeutic strategies for breast cancer treatment. One of the exciting developments in the past few years has been the realization that several chemotherapeutic agents, including microtubule-directed drugs such as paclitaxel, vinblastine and vincristine, exert their cytotoxic eects via the induction of apoptosis, or programmed cell death (Kaufmann and Earnshaw, 2000) . Thus, a hypothesis has been formulated that can explain how tumor cells acquire a broad drug resistance, namely by acquiring a resistance to apoptosis, the ultimate common pathway of chemotherapy-induced cell death (see e.g. Pusztai et al., 1998) . The factors that prevent tumor cells from undergoing drug-induced apoptosis in vivo and thus may help tumor cells to acquire drug resistance are largely unknown at present.
Integrins are a/b-heterodimeric membrane proteins that mediate cell adhesion to the surrounding extracellular matrix (ECM). In addition to their mechanistic role in anchoring the cells to the substratum, integrins have also the capacity to elicit a wide variety of intracellular signals that regulate cell behavior (Schwartz et al., 1995) . It is known that epithelial and endothelial cells are absolutely dependent on integrin-mediated cell attachment for their survival; thus, these cells undergo apoptosis upon loss of integrin-mediated cell attachment, a process referred to as anoikis (Frisch and Ruoslahti, 1997) . More recently, we and others have shown that integrinmediated cell attachment mediates survival signaling in many types of normal cells against dierent apoptotic stimuli, such as serum withdrawal (Lee and Juliano, 2000; O'Brien et al., 1996; Zhang et al., 1995) , activation-induced cell death in T lymphocytes (Aoudjit and Vuori, 2000) and ligation of death receptors in endothelial cells (Aoudjit and Vuori, 2001) . Among the signaling molecules involved in integrin-mediated cell survival is the focal adhesion kinase FAK (Almeida et al., 2000; Aoudjit and Vuori, 2000; Frisch et al., 1996; Gilmore et al., 2000; Hungerford et al., 1996; Ilic et al., 1998) , which becomes activated following integrin ligation and may in turn activate downstream survival pathways such as those composed of phosphatidylinositol 3'-kinase (PI 3-kinase) and the serine/threonine kinase Akt (Gilmore et al., 2000; Khwaja et al., 1997; Rytomaa et al., 2000) . Other survival pathways, such as the MAPK/ERK pathway (Aoudjit and Vuori, 2001; Le Gall et al., 2000) , NF-kB (Scatena et al., 1998) and Bcl-2-proteins (Rosen et al., 2000; Zhang et al., 1995) have also been implicated in integrin survival signaling in epithelial and endothelial cells. Integrin signaling has been demonstrated to regulate cell death and survival also in cancer cells. Thus, it has been shown that the avb3 integrin promotes survival of melanoma cells (Montgomery et al., 1994; Petitclerc et al., 1999) . Integrin-mediated cell attachment has also been shown to modulate cancer cell responses to chemotherapeutic agents (Damiano et al., 1999; Sethi et al., 1999; Uhm et al., 1999) . In adriamycin-resistant MCF-7 cells, enhanced expression of the a5b1 integrin and subsequent cell adhesion to ®bronectin correlate with the inhibition of apoptosis following serum withdrawal (Nista et al., 1997) . Furthermore, expression of the a6b1 integrin has been shown to be necessary not only for adhesion and invasion, but also for cell survival and tumor growth in vivo of the MDA-MB-435 metastatic breast cancer cell line (Wewer et al., 1997) . At present, the molecular events that mediate integrin survival signaling in cancer cells are poorly understood.
In the present work, we demonstrate that apoptosis induced by two microtubule-directed chemotherapeutic agents, paclitaxel and vincristine, is signi®cantly inhibited by b1 integrin signaling in metastatic breast cancer cells. Our results further demonstrate that integrin-mediated cell attachment protects breast cancer cells from drug-induced apoptosis by inhibiting the release of cytochrome c from mitochondria. Furthermore, we provide evidence that the integrinmediated inhibition of apoptosis and cytochrome c release in breast cancer are dependent on the PI 3-kinase/Akt survival pathway. Our results identify b1 integrin signaling as an important survival pathway in drug-induced apoptosis in breast cancer cells and suggest that activation of this pathway may contribute to the generation of drug resistant phenotype.
Results
Integrin-mediated cell adhesion inhibits drug-induced apoptosis in MDA-MB-231 and MDA-MB-435 cells Recent studies have indicated that matrix attachment is capable of modulating drug-induced apoptosis in some types of cancer cells, such as myeloma, glioma and small cell lung cancer (Damiano et al., 1999; Sethi et al., 1999; Uhm et al., 1999) , and we decided to examine whether the same is true for breast cancer cells. As cellular models for our studies, we utilized the classical breast cancer cell lines MDA-MB-231 and MDA-MB-435, both of which have been widely used in in vitro and in vivo studies. Importantly, it has been previously demonstrated that these metastatic breast cancer cells are sensitive to the death-inducing eects of the microtubule-targeting chemotherapeutic agents paclitaxel and vincristine (Srivastava et al., 1999; Yeung et al., 1999) , which, alone or in combination, are the drugs of choice in breast cancer chemotherapy. We found the same here; 24 h treatment of MDA-MB-231 and MDA-MB-435 cells with 50 nM paclitaxel or with 54 nM vincristine induced cell death in 50 and 70% of the cells, respectively, as monitored by Trypan blue exclusion assay (data not shown). In all the subsequent studies in this paper, both paclitaxel and vincristine were utilized; identical results with the two chemotherapeutic agents were obtained, and the results for paclitaxel are shown and discussed here.
Previous studies have demonstrated that MDA-MB-231 cells attach equally well on several ECM proteins, such as type I collagen, ®bronectin, laminin-1 and vitronectin (Lichtner et al., 1998; Lundstrom et al., 1998; van der Pluijm et al., 1997; Wong et al., 1998) , and we found the same here. Also of note, no dierences in cell survival were observed when MDA-MB-231 cells were plated on dierent matrix substrates or on the non-integrin ligand polylysine for extended periods of time in the absence of any drug treatment (not shown). In order to examine the potential survival role of matrix attachment in drug-induced apoptosis in breast cancer cells, MDA-MB-231 cells were plated on wells that had been coated with various ECM proteins, or as a control with the non-integrin ligand polylysine. The cells were then treated with dierent concentrations of paclitaxel for various amounts of time, and apoptosis was determined by DNA fragmentation assay or by Hoechst staining; similar results were obtained with the two methods. Also, similar results were obtained with all concentrations of paclitaxel and time points tested; results obtained under conditions in which the cells were treated with 50 nM of paclitaxel for 24 h are shown in the ®gures. As shown in Figure  1a , paclitaxel-treatment induced a signi®cant increase in DNA fragmentation in cells that had been plated on uncoated tissue culture dishes or on polylysine. Interestingly, a signi®cant inhibition in DNA fragmentation was observed in cells that had been plated on ®bronectin or type I collagen (37 and 42% inhibition, respectively). Cell attachment on two other matrix proteins, vitronectin ( Figure 1a ) and laminin-1 (data not shown), however, failed to signi®cantly protect the cells against drug-induced apoptosis. Thus, these results suggest that attachment-induced survival signaling may take place not only in an integrin-dependent, but also in an integrin-speci®c manner in breast cancer cells.
In order to determine which integrin(s) are involved in the inhibition of paclitaxel-induced apoptosis following MDA-MB-231 cell attachment to ®bronectin and collagen I, the cells were preincubated with blocking antibodies against various a and b subunits of integrins, and the ability of ®bronectin and collagen I to protect the cells from paclitaxel-induced apoptosis was determined. As shown in Figure 1b , incubation of MDA-MB-231 cells with antibodies that inhibit the function of the a5b1 integrin, a known ®bronectin receptor, completely abolished the ability of ®bronectin Cell adhesion regulates drug-induced apoptosis F Aoudjit and K Vuori to protect the cells against paclitaxel-induced apoptosis. Importantly, antibodies against another ®bronectin receptor, the a4b1 integrin, had no eect on cell survival. As expected, cell attachment assays demonstrated that a5b1 integrin contributes to MDA-MB-231 cell adhesion on ®bronectin (data not shown) (Lichtner et al., 1998; van der Pluijm et al., 1997) . Similar results were observed when the integrin speci®city for cell survival on collagen I was examined. The survival eect of collagen I was speci®cally and signi®cantly inhibited by antibodies against the a2b1 integrin, but not the a1b1 or the a3b1 integrins ( Figure 1c ). Cell attachment assays demonstrated that a2b1 integrin, which is a known collagen receptor, mediates MDA-MB-231 cell attachment to collagen I (data not shown) (Lichtner et al., 1998; Lundstrom et al., 1998; van der Pluijm et al., 1997) . Taken together, our results indicate that signaling via the a2b1 and a5b1 integrins signi®cantly inhibits chemotherapeutic agent-induced apoptosis in MDA-MB-231 cells.
We also examined the capability of de®ned matrix proteins and integrins to support cell survival in MDA-MB-435 cells. Previous studies have demonstrated that these cells, similar to MDA-MB-231 cells, attach to ®bronectin, collagen and laminin-1 (Seftor et al., 1998; Shaw et al., 1996) . Similar to MDA-MB-231 cells, plating of MDA-MB-435 cells to uncoated dishes or to dishes that had been coated with polylysine failed to protect the cells against paclitaxel-induced apoptosis ( Figure 2a ). Interestingly, cell attachment to collagen I and ®bronectin also failed to provide protection against paclitaxel-induced apoptosis, despite the fact that these cells adhere on collagen I and ®bronectin via the a2b1 and a5b1 integrins, respectively (data not shown) (Seftor et al., 1998; Shaw et al., 1996) . As noted above, ligation of these integrins provided protection against paclitaxel-induced apoptosis in MDA-MB-231 cells. When the MDA-MB-435 cells were plated on laminin-1, however, a signi®cant inhibition in DNA fragmentation was observed in response to paclitaxel treatment ( Figure 2a ). This protective eect was signi®cantly blocked by preincubating the cells with antibodies against the a6b1 integrin, which is a known laminin receptor in these cells ( Figure 2b ; Shaw et al., 1996) . These results are in contrast to our ®ndings in MDA-MB-231 cells; these cells attach to laminin-1, but via the a3b1 integrin (van der Pluijm et al., 1997), and attachment of MDA-MB-231 cells on laminin-1 failed to support survival of the cells upon paclitaxel treatment. Taken together, our studies indicate that matrix attachment provides protection against drug-induced apoptosis in breast cancer cells, and that this protection takes place in a matrix protein-, integrin-and cell type-speci®c manner.
b1 integrin-mediated protection against drug-induced apoptosis is PI 3-kinase/Akt-dependent in breast cancer cells
In many cell types, matrix attachment has been shown to result in activation of the PI 3-kinase/Akt pathway (see Giancotti and Ruoslahti, 1999; Schlaepfer et al., 1999) and we found the same here for MDA-MB-231 and MDA-MB-435 cells. Adhesion of MDA-MB-231 Prior to cell attachment, the cells were preincubated or not for 30 min with 10 mg/ml of various inhibitory antibodies against dierent a and b subunits of integrins as indicated. The cells were treated or not with 50 nM paclitaxel for 24 h and apoptosis was determined as above cells to ®bronectin or collagen I and adhesion of MDA-MB-435 cells to laminin-1 induced a twofold increase in Akt phosphorylation, which was completely blocked by the addition of the PI 3-kinase inhibitor Ly294002 (data not shown). Furthermore, activation of the PI 3-kinase/Akt pathway has been shown to mediate integrin survival signaling in epithelial cells and protect them against detachment-and serum withdrawal-induced apoptosis (Khwaja et al., 1997; Lee and Juliano, 2000) . Also, exogenous activation of this pathway has been demonstrated to inhibit chemotherapeutic agent-induced apoptosis (Gooch et al., 1999) . To investigate the role of PI 3-kinase/Akt pathway in cell survival downstream of b1 integrins in breast cancer cells, two lines of experiments were carried out. We ®rst examined the eect of the PI 3-kinase inhibitor Ly294002 on the capability of b1 integrin ligation to protect breast cancer cells against paclitaxel-induced apoptosis. As shown in Figure 3 , preincubation of MDA-MB-231 and MDA-MB-435 cells with the PI 3-kinase inhibitor completely abolished the protective eects of ®bronectin and collagen I and laminin-1, respectively, against paclitaxel-induced apoptosis. Importantly, treatment of the cells with Ly294002 per se did not aect cell viability, but it did potentiate the eect of paclitaxel on cells plated on polylysine ( Figure 3) . As an additional line of investigation, we examined the eect of dominantnegative forms of PI 3-kinase and Akt on integrinmediated protection against paclitaxel-induced apoptosis. To this end, MDA-MB-231 cells were transfected with plasmids coding for dominant-negative forms of PI 3-kinase or Akt together with a plasmid encoding bgalactosidase. Cell survival and apoptosis was then analysed in b-galactosidase-positive cells as described in Materials and methods. Importantly, expression of these constructs by themselves had no eect on cell survival and apoptosis in MDA-MB-231 cells ( Figure  4 ). As shown in Figure 4a , paclitaxel-treatment induced cell death in 450% of b-galactosidase-positive cells that had been plated on polylysine, while 70 ± 75% of the cells survived when attached on ®bronectin or collagen I. However, when dominant-negative forms of PI 3-kinase or Akt were expressed in the cells, the ability of ®bronectin and collagen I to protect the cells from paclitaxel-induced apoptosis was completely abolished (Figure 4a ). Further studies indicated that coexpression of activated form of Akt with the dominant-negative form of PI 3-kinase restored the survival eect of ®bronectin and collagen I (Figure 4b ). Thus, we conclude that integrin-mediated activation of the PI 3-kinase/Akt pathway mediates the protective eects against paclitaxel-induced apoptosis in breast cancer cells.
Paclitaxel-treatment induces cytochrome c release from mitochondria and decreases Bcl-2 protein levels; these events are blocked by integrin-mediated cell attachment in breast cancer cells Recent reports have indicated that chemotherapeutic agent-induced apoptosis is, in some cases, associated with the release of cytochrome c from the mitochondria (Kaufmann and Earnshaw, 2000) , which is a critical event in the activation of caspase-9 and cell death (Green and Reed, 1998; Li et al., 1997). In Cell adhesion regulates drug-induced apoptosis F Aoudjit and K Vuori particular, it has been shown that paclitaxel induces cytochrome c release in MDA-MB-468 breast carcinoma cell line (Kottke et al., 1999) . Of further note, it has been demonstrated recently that matrix attachment inhibits cytochrome c release, at least in MDCK epithelial cells. Importantly, this inhibition was shown to take place via activation of the PI 3-kinase/Akt pathway (Rytomaa et al., 2000) . Therefore, we decided to examine whether paclitaxel-induced apoptosis in breast cancer cells is associated with cytochrome c release, and whether appropriate cell ± matrix interaction in turn might block this event. As shown in Figure  5 , treatment of polylysine-attached MDA-MB-231 cells with paclitaxel results in the release of cytochrome c in the cytoplasm, as detected by immunoblot analysis on the cytosolic fractions. Attachment of the cells to ®bronectin or collagen I signi®cantly blocked cytochrome c release in response to paclitaxel. Importantly, this inhibition was completely abolished when the cells were treated with the PI 3-kinase inhibitor Ly294002. Similarly, adhesion of MDA-MB-435 cells on laminin-1 inhibited paclitaxel-induced cytochrome c release, which was reversed by the treatment of the cells with the PI 3-kinase inhibitor (data not shown). Taken together, these results indicate that integrin signaling inhibits paclitaxel-induced cytochrome c release and that this inhibition is mediated by the PI 3-kinase/Akt pathway. Several reports have suggested that the balance between the pro-and anti-apoptotic proteins of the Bcl-2 family is a determining factor in the control of cytochrome c release and apoptosis in various cell types (Gross et al., 1999) . Previously, integrin signaling has been shown to promote cell survival by increasing the levels of the anti-apoptotic Bcl-2 protein (Zhang et al., 1995) , and by inhibiting the function of the proapoptotic protein Bax (Gilmore et al., 2000; Rytomaa et al., 2000) . Thus, we decided to examine whether paclitaxel-induced apoptosis is associated with changes in Bcl-2 and Bax, and whether appropriate matrix attachment in turn might regulate these events in breast cancer cells. As shown in Figure 6 , paclitaxel treatment, or attachment of cells to ®bronectin or collagen I, had no eect on the expression levels of Bax in MDA-MB-231 cells. We also found that paclitaxeltreatment did not induce Bax translocation to the mitochondria; this event has been associated with induction of cytochrome c release, and in some cell types, integrin signaling has been shown to prevent Bax translocation in response to certain apoptotic stimuli (Gilmore et al., 2000; Rytomaa et al., 2000) . However, we found that treatment of polylysine-plated MDA-MB-231 cells with paclitaxel resulted in a signi®cant decrease in the protein levels of Bcl-2. Attachment of the cells to ®bronectin and collagen I in turn blocked the paclitaxel-induced decrease in Bcl-2 protein levels. Interestingly, this inhibition by matrix attachment was completely abolished when the cells were pre-treated with the PI 3-kinase inhibitor Ly294002. Taken together, our results demonstrate that integrinmediated inhibition of paclitaxel-induced apoptosis correlates with sustained high levels of Bcl-2 in a PI 3-kinase-dependent manner.
Discussion
In order to acquire drug resistance, tumor cells must escape the initial cytotoxic eects of chemotherapeutic agents. Understanding of the molecular signals that contribute to the inhibition of chemotherapeutic agentinduced apoptosis in tumor cells may provide better strategies for new drug design in diseases such as breast cancer. It is well known that integrin-mediated cell Figure 3 b1 integrin signaling inhibits paclitaxel-induced apoptosis in a PI 3-kinase-dependent manner. MDA-MB-231 (a) and MDA-MB-435 cells (b) were plated on dishes that had been coated or not with polylysine (PLL) or with various ECM proteins, such as ®bronectin (FN), collagen I (COLL) or laminin-1 (LN), as indicated, and simultaneously treated or not with the PI 3-kinase inhibitor Ly294002 (25 mM) for 1 h. Paclitaxel (50 nM) was then added to the wells for an additional 24 h, after which apoptosis was determined as above. The results are representative of three independent experiments Oncogene Cell adhesion regulates drug-induced apoptosis F Aoudjit and K Vuori attachment protects normal mammary epithelial cells from apoptosis (Frisch and Ruoslahti, 1997) , and the mechanisms underlying integrin-mediated survival signaling have started to become uncovered. It is less clear, however, what role integrin signaling has in regulation of cell survival and apoptosis in transformed breast cancer cells. In this study, we demonstrate that in two metastatic breast cancer cell lines, MDA-MB-231 and MDA-MB-435, b1 integrin signaling inhibits signi®cantly apoptosis induced by paclitaxel and vincristine, two microtubule-directed drugs that are widely used in the clinic in breast cancer therapy. Taken together with previous reports, which have shown that integrin signaling blocks drug-induced apoptosis in myeloma (Damiano et al., 1999) , glioma (Uhm et al., 1999) and in non small lung cancer cells (Sethi et al., 1999) , our results demonstrate that integrin signaling is an important survival pathway in cancer cells and can contribute to the development of drug resistance.
Our results demonstrate that a2b1 and a5b1 integrinmediated cell attachment to collagen I and ®bronectin, respectively, inhibits chemotherapeutic agent-induced apoptosis in MDA-MB-231 cells. In MDA-MB-435 cells, however, it is the laminin-1-binding integrin a6b1 that mediates protective eects against drug-induced apoptosis, despite the fact that these cells also attach to collagen I and ®bronectin. These ®ndings suggest that breast cancer cells may respond dierentially to their tissue microenvironment, depending on, for example, the overall expression pro®le and/or activation state of the integrin receptors on the cell surface, and on other signaling events active in the cells. It is interesting to note that the observed integrin-speci®city in the two breast cancer cell lines may be of physiological signi®cance. Thus, MDA-MB-231 cells are known to metastasize avidly to bone, in which type I collagen is very abundant (Coleman and Rubens, 1987) . Further, it has been shown that a2b1 integrin-mediated attachment to collagen I is necessary for bone metastasis to take place by breast cancer cells (Lundstrom et al., 1998; van der Pluijm et al., 1997) . In turn, laminin-a6b1 integrin interaction has been shown to enhance survival and in vivo tumor growth of MDA-MB-435 cells (Wewer et al., 1997) . Thus, acquisition of a speci®c`tumor phenotype' of adhesive interactions may not only be required for tumorigenicity per se and for metastasis to certain target organs, but it may also be of importance in providing cell survival signaling against chemotherapy.
Our studies identify a functional role for the PI 3-kinase/Akt pathway in integrin-mediated survival signaling against drug-induced apoptosis. We found that the protective eects of collagen I and ®bronectin in MDA-MB-231 cells and of laminin-1 in MDA-MD435 cells were completely abolished in the presence of the PI 3-kinase inhibitor Ly294002. Further, expression of dominant-negative forms of PI 3-kinase and Akt also blocked the ability of integrin signaling to protect from drug-induced apoptosis. In agreement with previous studies that have shown that the PI 3-kinase/Akt pathway inhibits several forms of cell death (Datta et al., 1999) , our results demonstrate that this pathway also inhibits drug-induced apoptosis and may therefore contribute to the development of drug resistance. As a corollary, inhibition of PI 3-kinase activity in tumor cells might be bene®cial for chemotherapy.
In previous studies, the mechanisms by which integrins modulate drug-induced apoptosis have not been addressed. Our results indicate that one potential mechanism by which integrins inhibit drug-induced apoptosis, at least in breast cancer cells, is by blocking the release of cytochrome c from the mitochondria. We found that ligation of b1 integrins with their respective ECM ligands signi®cantly diminished the release of cytochrome c from the mitochondria into the cytoplasm. The release of cytochrome c into the cytosol is a critical event in the activation of the apoptotic signaling cascade. In cytosol, cytochrome c is a component of the`apoptosome' complex that results in the activation of caspase-9, which then activates further downstream caspases, resulting in irreversible cell damage and death (Li et al., 1997) . The importance of cytochrome c release in paclitaxel-induced apoptosis is underscored by our ®nding that a speci®c caspase-9 inhibitor (z-LEHD) blocks paclitaxel-induced apoptosis by about 80% (data not shown). It is thus likely that integrin signaling, by blocking the release of cytochrome c, inhibits the activation of caspase-9 and subsequently cell death in paclitaxel-treated breast cancer cells. Our results further demonstrate that the inhibition of cytochrome c release by integrins ligation is mediated by the PI 3-kinase/Akt pathway; thus, the inhibition is completely abolished by the PI 3-kinase inhibitor Ly294002. We have also found that exogenous expression of activated forms of PI 3-kinase and Akt signi®cantly reduces the release of cytochrome c in response to drug treatment, and promotes cell survival on`non-survival' substrates, such as polylysine (data not shown). The mechanisms by which cytochrome c is released from the mitochondria in response to death signals are not well understood at present. It is believed, however, that mitochondrial integrity and the release of cytochrome c is regulated by the balance of pro-and anti-apoptotic proteins of the Bcl-2 family. While the pro-apoptotic proteins Bax and Bak (Jurgensmeier et al., 1998; Shimizu et al., 1999) have been shown to facilitate cytochrome c release, the antiapoptotic proteins Bcl-2 and Bcl-xL antagonize the release (Kluck et al., 1997; Shimizu et al., 1999; Yang et al., 1997) . Therefore, it is possible that integrin signaling and the PI 3-kinase/Akt pathway inhibit drug-induced cytochrome c release by modulating the balance between the anti-and the pro-apoptotic proteins of the Bcl-2 family members. Importantly, previous studies have demonstrated that paclitaxelinduced cell death is associated with phosphorylation and subsequent degradation of the Bcl-2 protein (Chadebech et al., 1999; Kottke et al., 1999; Srivastava et al., 1999; Wang and Passaniti, 1999) ; in accordance with these studies, we found that paclitaxel-treatment results in a decrease in Bcl-2 protein levels in breast cancer cells (see Figure 6 ). Furthermore, we found that appropriate integrin ± matrix interaction blocked the decrease in the Bcl-2 levels in a PI 3-kinase-dependent manner. Previously, ligation of the a5b1 integrin, but Figure 5 Paclitaxel-induced cytochrome c release from mitochondria is blocked by adhesion on ®bronectin (a) and on collagen I (b) in a PI 3-kinase-dependent manner in MDA-MB-231 cells. MDA-MB-231 cells were plated on polylysine or various matrix proteins as indicated, and treated with paclitaxel (50 nM) for 12 h. As indicated, the cells were preincubated or not with the PI 3-kinase inhibitor Ly294002 (25 mg/ml) for 1 h prior to the addition of paclitaxel. Cytosolic cell extracts were prepared as described in Material and methods and analysed by immunoblotting using an anti-cytochrome c antibody (upper panels). The blots were stripped and reprobed with an anti-GAPDH control antibody to con®rm equal loading (lower panels) Figure 6 Paclitaxel induces downregulation of Bcl-2 protein levels, which is inhibited by adhesion on ®bronectin and collagen I in a PI 3-kinase-dependent manner in MDA-MB-231 cells. MDA-MB-231 cells were plated on polylysine or on various matrix proteins as indicated, and treated or not with paclitaxel (50 nM) for 12 h. As indicated, some of the cells were preincubated with the PI 3-kinase inhibitor Ly294002 (25 mg/ml) for 1 h prior to the addition of paclitaxel. Cell extracts were prepared as described in Material and methods and analysed by anti-bcl-2 (upper panel) and anti-Bax immunoblotting (lower panel). Relative levels of Bcl-2 were determined by a densitometric analysis. The blots were stripped and reprobed with an anti-GAPDH control antibody to con®rm equal loading (not shown) not of the avb1 integrin, which is also a ®bronectin receptor, has been shown to induce cell survival and enhanced expression of Bcl-2 in ovarian epithelial cells (Zhang et al., 1995) . In glioma cells, vitronectinmediated protection against chemotherapeutic agentinduced apoptosis correlates with increased ratios of Bcl-2:Bax and Bcl-xL:Bax (Uhm et al., 1999) . The mechanisms by which integrin signaling regulates the levels of Bcl-2 are not known; our results suggest that it may involve activation of the PI 3-kinase/Akt pathway. In this regard, it has recently been demonstrated that Bcl-2 gene expression is regulated by Akt (Pugazhenthi et al., 2000) . Integrin-mediated cell survival has also been correlated with the regulation of the pro-apoptotic protein Bax. Thus, integrin signaling has been shown to protect mammary epithelial cells from anoikis by regulating the apoptotic function of Bax through its conformation and subcellular localization (Gilmore et al., 2000) . Furthermore, inhibition of integrin signaling by matrix detachment of MDCK cells induces cytochrome c release, which can be blocked by expression of activated form of Akt; this inhibition in turn correlates with inhibition of Bax translocation to mitochondria (Rytomaa et al., 2000) . Our results indicate that paclitaxel-induced apoptosis is not associated with Bax translocation to the mitochondria or with changes in Bax expression. We further found that integrin signaling has no eect on Bax expression or subcellular localization in breast cancer cells. Thus, we propose that one mechanism by which integrin signaling blocks cytochrome c release in paclitaxel-treated breast cancer cells is by maintaining high protein levels of Bcl-2. This does not rule out the possibility that additional members of the Bcl-2 family, such as Bad (Page et al., 2000) , might also be involved in paclitaxel-induced cytochrome c release and function as targets for integrin survival signaling.
It is also possible that integrin signaling and the PI 3-kinase/Akt pathway could regulate apoptosis at an additional level upstream or downstream of cytochrome c release. For example, caspase-9 itself has been shown to be phosphorylated and subsequently inactivated by Akt (Cardone et al., 1998) . Also, binding of paclitaxel and vincristine to microtubules has been shown to inhibit cell cycle progression and to induce cell cycle arrest prior to the induction of apoptosis in cancer cells (Blagosklonny et al., 1997; Haldar et al., 1997; Kumar, 1981; Srivastava et al., 1998) . Thus, integrin signaling could also modify druginduced apoptosis by regulating cell cycle. In this respect, it has been shown recently that in myeloma cells, b1 integrin-mediated cell attachment to ®bronec-tin upregulates the levels of the cell cycle inhibitor p27kip, which contributes to adhesion-mediated drug resistance in these cells (Hazlehurst et al., 2000) . It is also possible that activation of survival pathways other than the PI 3-kinase/Akt pathway may contribute to inhibition of drug-induced apoptosis downstream of integrins. It has been shown recently that inhibition of the MAPK/ERK survival pathway enhances paclitaxelinduced apoptosis in several types of cancer cells, including breast cancer (MacKeigan et al., 2000) . It is known that integrin ligation activates the Erk kinase cascade, which contributes to adhesion-mediated survival signaling in some cell types (Aoudjit and Vuori, 2001; Le Gall et al., 2000) . Similar to MacKeigan et al. (2000) , we found that paclitaxelinduced apoptosis in MDA-MB-231 is signi®cantly enhanced when the cells are treated with the MEK inhibitor PD98059 (data not shown). However, addition of the MEK inhibitor did not aect the ability of ®bronectin or collagen I to protect the cells against paclitaxel-induced apoptosis. It therefore seems that activation of the ERK pathway is not necessary for integrin-mediated inhibition of paclitaxel-induced apoptosis to take place in breast cancer cells. A full understanding of the molecular events that mediate integrin-dependent survival in cancer cells may provide new therapeutic tools for cancer treatment.
Materials and methods

Cells and reagents
Human breast carcinoma cell lines MDA-MB-231 and MDA-MB-435 were from ATCC (Rockville, MD, USA), and they were cultured in RPMI 1640 supplemented with 10% FCS, 2 mM L-Glutamine, 50 mg/ml streptomycin and 50 U/ml penicillin (Irvine Scienti®c, Santa Ana, CA, USA). Chemotherapeutic agents paclitaxel and vincristine were from Sigma. The PI 3-kinase inhibitor Ly294002 was from Calbiochem (La Jolla, CA, USA). Puri®ed bovine type I collagen and mouse laminin-1 were from Becton Dickinson (Bedford, MA, USA) and Gibco ± BRL (Grand Island, NY, USA) respectively. Human ®bronectin was obtained from Finnish Red Cross (Helsinki, Finland), vitronectin and polylysine from Sigma. Inhibitory anti-integrin antibodies were from Chemicon (Temecula, CA, USA).
Plasmids and transient transfections
Cells were transiently transfected by using the Novafector reagent from VennaNova, LLC (Pompano Beach, FL, USA) according to the manufacturer's instructions. Cells were grown to 80% con¯uency on 6-well plates or on 10 cm dishes and transfected with 10 or 20 mg of total DNA. Fortyeight hours later, the cells were washed with PBS and used for subsequent experiments. The plasmids encoding activated and dominant-negative forms of PI 3-kinase and Akt were obtained from Drs Jerrold Olefsky (UCSD, San Diego, CA, USA) and Phil Tsichlis (Thomas Jeerson University, Philadelphia, PA, USA), respectively. The b-galactosidase expressing plasmid was from Invitrogen (Carlsbad, CA, USA).
Cell death experiments and apoptosis assays
Cells were grown to 80% of con¯uence, detached and plated on wells that were uncoated, or had been coated with 25 mg/ ml of various ECM proteins, including ®bronectin, collagen type I, laminin-1 and vitronectin, or with 25 mg/ml of the non-integrin ligand polylysine. The cells were treated with dierent concentrations of paclitaxel or vincristine for 24 or 48 h. In some experiments, the cells were ®rst preincubated with the Ly294002 inhibitor for 1 h before adding the chemotherapeutic drugs.
Apoptosis was monitored by using a cell-death detection ELISA kit measuring DNA fragmentation (Boehringer ± Mannheim) according to manufacturer's instructions or by Hoechst staining as previously described (Aoudjit and Vuori, 2000) . Alternatively, cell death was determined by a bgalactosidase assay as described (Khwaja et al., 1997) . Brie¯y, the cells were transfected with the b-galactosidase reporter plasmid together with a control vector or with vectors coding for activated-or dominant-negative forms of PI 3-kinase and Akt. After transfection, the cells were seeded in wells that had been coated or not with ECM proteins/polylysine as described above and treated with paclitaxel for 24 h. The cells were then ®xed and stained with X-gal for bgalactosidase activity. Positively stained cells were scored as normal or apoptotic on the basis of cellular morphology (Khwaja et al., 1997) .
Cytochrome c release, Akt phosphorylation and Bcl-2/Bax immunoblotting Cytosolic fractions were prepared as described in (Samali et al., 1999) . Brie¯y, the cells were washed and resuspended in 100 ml of mitochondrial buer (70 mM Tris-base, 0.25 M sucrose and 1 mM EDTA, pH 7.4) for 10 min on ice. An equal volume of the MES buer (19.8 mM EGTA, 19.8 mM EDTA, 0.25 mM D-mannitol and 19.8 mM MES, pH 7.4) containing 1 mg/ml of digitonin was added to the samples until 90% of the cells become permeabilized as determined by Trypan blue exclusion. The cells were centrifuged at 900 g for 5 min and the supernatant was further centrifuged for 15 min at 20 000 g to obtain the cytosolic fraction. Samples were then processed for immunoblot analysis. To ensure the purity of the fractions, we performed an immunoblot analysis with antibodies against the mitochondrial cytochrome c oxidase (antibody 20E8-C12, Molecular Probes, Eugene, OR, USA) and found that only the unbroken cell fraction, which contains the mitochondria, and not the cytosolic fraction, contains cytochrome c oxidase (data not shown). Cytochrome c release was detected in the cytoplasmic fractions using the anti-cytochrome c antibody (clone 7H8.2C12) from Pharmingen (San Diego, CA, USA).
For Akt phosphorylation, the cells were plated on wells that had been coated or not with polylysine, ®bronectin or collagen I in the presence or absence of paclitaxel (50 nM) for 2 h. The cells were detached and washed with PBS and lysed in RIPA buer as described previously . Immunoblot analysis was carried out using an antiphospho-Akt antibody (Ser 473) from Cell Signaling Technology (Beverly, MA, USA). The expression levels of Akt in the dierent samples were determined by using antiAkt antibody C-20 from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The expression of Bcl-2 and Bax proteins was determined in total cell lysates by immunoblotting with anti-Bcl-2 (Clone 7) and anti-Bax (clone 3) antibodies from Transduction Laboratories (Lexington, KY). The blots were also probed with anti-GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) monoclonal antibody (Chemicon International, Inc.) to serve as an internal protein control. In all experiments, immunoblots were visualized by using an HRPO-conjugated secondary antibody followed by enhanced chemiluminescence detection (Pierce, Rockford, IL, USA).
Abbreviations ECM, extracellular matrix; GFP, green¯uorescent protein; PI 3-kinase, phosphatidyl inositol 3'-kinase.
